Torrent Pharma Gets CDSCO Panel Nod To study antidiabetic FDC Empagliflozin plus Sitagliptin

Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus. Sitagliptin inhibits DPP-4 which leads to increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide(GIP), decreased levels of glucagon, and a stronger insulin response to glucose

Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIP. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasis. Reduced inhibition of incretins increases insulin synthesis and decreases glucagon release in a manner dependent on glucose concentrations. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c).

At the recent SEC meeting for Endocrinology and Metabolism held on 14th December 2023, the expert panel reviewed the proposal presented by the drug major Torrent Pharmaceuticals along with the revised Phase III clinical trial protocol of the antidiabetic drug Empagliflozin plus Sitagliptin Phosphate Monohydrate.

After detailed deliberation, the committee recommended a grant of permission to conduct the Phase III clinical trial as per the revised protocol.

Furthermore, the expert panel suggested that the firm should submit a Phase III clinical trial report to CDSCO for further review by the committee.

Also Read:Conduct Phase III CT of Triptorelin to treat chronic pain linked to endometriosis: CDSCO Panel Tells Dr Reddy's Lab